Overview

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Phase:
Phase 2
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Formoterol Fumarate